Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Oncotarget|April 23, 2016
MET expression during prostate cancer progressionEsther I Verhoef, Kimberley Kolijn, Maria J De Herdt, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2016
Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinomaCharlotte F Kweldam, Intan P Kümmerlin, Daan Nieboer, et al.
European Urology|August 24, 2019
Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade GroupsGeert J L H van Leenders, Charlotte F Kweldam, Eva Hollemans, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 21, 2020
Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patientsEva Hollemans, Esther I Verhoef, Chris H Bangma, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 22, 2020
Clinicopathological characteristics of glomeruloid architecture in prostate cancerEva Hollemans, Esther I Verhoef, Chris H Bangma, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 27, 2021
Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patientsTim Hansum, Eva Hollemans, Esther I Verhoef, et al.
Oncotarget|February 25, 2016
Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinomaMaria J De Herdt, Stefan M Willems, Berdine van der Steen, et al.
Oncotarget|December 19, 2018
Tissue proteomics outlines AGR2 AND LOX5 as markers for biochemical recurrence of prostate cancerGiovanny Rodríguez-Blanco, Lona Zeneyedpour, Diederick Duijvesz, et al.
Cells|November 26, 2022
Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor SignalingAnnelies Van Hemelryk, Ingrid Tomljanovic, Corrina M A de Ridder, et al.
Cancer Research|November 13, 2014
SYK is a candidate kinase target for the treatment of advanced prostate cancerVeerander P S Ghotra, Shuning He, Geertje van der Horst, et al.
Pageof 4